Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 316765. Отображено 100.
05-01-2012 дата публикации

Dendrimer based nanodevices for therapeutic and imaging purposes

Номер: US20120003155A1

A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer. A method of site-specific delivery of a therapeutically active agent, by attaching a therapeutically active agent to a PAMAM dendrimer or multiarm PEG polymer using a disulfide bond, administering the PAMAM dendrimer or multiarm PEG polymer to a patient in need of treatment, localizing the dendrimer or multiarm PEG polymer to a site in need of treatment, and releasing the therapeutically active agent at the site in need of treatment.

Подробнее
05-01-2012 дата публикации

Biologically active food supplement

Номер: US20120003200A1
Принадлежит: Individual

A biologically active food supplement intended to increase the athletes' muscle mass comprises Leuzea (or other medicinal plant containing ecdysteroids), male bee brood, ascorbic acid (Vitamin C), Vitamin E, and excipients (calcium stearate, talc, lactose) with the following ratio of components (mass %): Male bee brood 1-70; Leuzea 5-70; Ascorbic acid 1-70; Vitamin E 0.05-30; calcium stearate 0.92-0.95, talc 3-6, lactose—the rest.

Подробнее
05-01-2012 дата публикации

Yeast ectopically expressing abnormally processed proteins and uses therefor

Номер: US20120003243A1

Disclosed are yeast ectopically expressing abnormally processed proteins and methods of screening to identify compounds that modulate the function of such abnormally processed proteins in yeast. Compounds identified by such screens can be used to treat or prevent diseases associated with abnormally processed proteins or protein misfolding. Such diseases include Parkinson's Disease, Parkinson's Disease with accompanying dementia, Lewy body dementia, Alzheimer's disease with Parkinsonism, and multiple system atrophy.

Подробнее
05-01-2012 дата публикации

Pharmaceutical compositions of dextran polymer derivatives

Номер: US20120003282A1
Принадлежит: Bend Research Inc

Pharmaceutical compositions are provided comprising an active agent and a dextran polymer derivative. The compositions include from 0.01 to 99 wt % of an active agent and from 1 to 99.99 wt % of a dextran polymer derivative. The dextran polymer derivative is selected from dextran acetate, dextran propionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran propionate succinate, dextran acetate propionate succinate, and mixtures thereof.

Подробнее
05-01-2012 дата публикации

Formulation Comprising Bioactive Agents And Method Of Using Same

Номер: US20120004170A1

Disclosed are methods of making bioactive BMP-2 microparticles and methods of using the microparticles.

Подробнее
05-01-2012 дата публикации

Process for production of orally ingestible composition containing arabinofuranosyl vitexin, and use of the composition

Номер: US20120004193A1
Автор: Shuichi Kusano
Принадлежит: Fuji Sangyo Co Ltd

A method for producing an orally ingestible composition containing an arabinofuranosyl vitexin and/or a hydrolysate thereof by using Basella alba as a raw material. The product of such method has a sedative effect and a sleep-inducing effect.

Подробнее
05-01-2012 дата публикации

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

Номер: US20120004206A1

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

Подробнее
05-01-2012 дата публикации

N-oxides of 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives useful as nicotinic acetylcholine receptor ligands

Номер: US20120004214A1
Принадлежит: Neurosearch AS

This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. Formula (I) a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, wherein Ar represents an indolyl group, which indolyl may optionally be substituted one or more times with substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, alkyl, hydroxy and alkoxy.

Подробнее
05-01-2012 дата публикации

Modulators of atp-binding cassette transporters

Номер: US20120004216A1
Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including CF Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Подробнее
05-01-2012 дата публикации

Method of Inhibition of Respiratory Depression Using Positive Allosteric AMPA Receptor Modulators

Номер: US20120004219A1
Автор: John Greer
Принадлежит: University of Alberta

The invention is directed to a method for alleviating respiratory depression in a subject as a result of disease of pharmacological agents such as opiates, opioids or barbiturates. The invention also discloses pharmaceutical compositions for use with the method, the composition containing in combination, an analgesic, anaesthetic, or a sedative and a positive allosteric AMPA receptor modulator in an amount sufficient to reduce or inhibit respiratory depression caused by the analgesic, anaesthetic, or sedative.

Подробнее
05-01-2012 дата публикации

Organic compounds

Номер: US20120004247A1
Принадлежит: NOVARTIS AG

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein R 1 , R 2 and R 3 are as defined herein.

Подробнее
05-01-2012 дата публикации

Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy

Номер: US20120004251A1
Принадлежит: GW Pharma Ltd, Otsuka Pharmaceutical Co Ltd

This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.

Подробнее
05-01-2012 дата публикации

New ccr2 receptor antagonists and uses thereof

Номер: US20120004252A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.

Подробнее
05-01-2012 дата публикации

Method of treatment or prophylaxis

Номер: US20120004259A1
Принадлежит: SPINIFEX PHARMACEUTICALS PTY LTD

The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin II receptor 2 (AT 2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of neuropathic pain, including mechanical hyperalgesia, thermal or mechanical allodynia, diabetic pain and entrapment pain, in vertebrate animals and particularly in human subjects. The AT 2 receptor antagonists may be provided alone or in combination with other compounds such as those that are useful in the control of neuropathic conditions.

Подробнее
05-01-2012 дата публикации

Compounds for the treatment of pathologies associated with aging and degenerative disorders

Номер: US20120004263A1
Принадлежит: University of Pittsburgh

The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and/or reducing the severity and/or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder.

Подробнее
20-11-2014 дата публикации

УСТАНОВКА ДЛЯ ОСУЩЕСТВЛЕНИЯ СПОСОБА ПОЛУЧЕНИЯ МИКРОСФЕР ОСНОВАНИЯ НАЛТРЕКСОНА, ВКЛЮЧЕННОГО В ПОЛИМЕРНУЮ МАТРИЦУ

Номер: RU0000148050U1

1. Установка для осуществления способа получения микросфер основания налтрексона, включенного в матрицу из биоразлагаемого полимера, выбранного из группы, состоящей из полилактида, полигликолида и полилактид-ко-гликолида, отличающаяся тем, что включает 1) микроканальный модуль, который является проточным реактором с диаметром каналов от 25 мкм до 0,5 мм, имеющим Т-образное или Х-образное пересечение каналов под углом 90°, или Y-образное пересечение каналов под углом от 20 до 70°, предназначенный для смешения объединенного раствора основания налтрексона в первом органическом растворителе, выбранном из группы, состоящей из хлористого метилена, хлороформа, тетрахлорида углерода, этиленхлорида, этилендихлорида и бензилового спирта, и полимера во втором органическом растворителе, выбранном из группы, состоящей из хлористого метилена, хлороформа, тетрахлорида углерода, этиленхлорида, этилендихлорида, этилацетата при условии, что если первый органический растворитель является бензиловым спиртом, то второй органический растворитель является этилацетатом, с первой водной диспергирующей фазой, содержащей 0,5-5,0% (мас./об.) поливинилового спирта (ПВС), для генерирования капель дисперсии за счет разделения потока объединенного раствора потоком первой водной диспергирующей фазы при соотношении постоянных расходов водной фазы и объединенного раствора от 100 до 4 и расходе объединенного раствора 0,05-1,0 мкл/с получением дисперсной системы; и 2) реактор смешения, представляющий каскад из двух или трех реакторов смешения, входом первого реактора связанный по потоку дисперсной системы с выходом микроканального модуля, где - первый из реакторов каскада выходом связан по потоку со входом последующего реактора и предназначен для приготовления второй водной диспергирующей фазы, содержащей 0,25-1,0% (мас./об.) ПВС, объединения дисперсной системы со второй водной диспергирующей фазой и механического воздействия в течение промежутка времени от 8 до 20 часов в интервале температуры от 4 до ...

Подробнее
12-01-2012 дата публикации

ANTI-Aß OLIGOMER HUMANIZED ANTIBODY

Номер: US20120009179A1
Принадлежит: Kyowa Hakko Kirin Co Ltd

An anti-Aβ oligomer humanized antibody which does not bind to Aβ monomers and specifically binds only to Aβ oligomers; an anti-cognitive dysfunction agent, an agent for treating Alzheimer's disease, an agent for suppressing formation of neuritic plaque and an inhibitor of formation of Aβ amyloid fiber comprising the antibody as an active ingredient; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the antibody.

Подробнее
12-01-2012 дата публикации

Modified Fc Molecules

Номер: US20120009205A1
Принадлежит: AMGEN INC

Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them. A DNA encoding the inventive composition of matter, an expression vector containing the DNA, and a host cell containing the expression vector are also disclosed.

Подробнее
12-01-2012 дата публикации

Monoparamunity inducers based on attenuated rabbit myxomaviruses

Номер: US20120009217A1
Автор: Anton Mayr, Barbara Mayr
Принадлежит: Individual

The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.

Подробнее
12-01-2012 дата публикации

Modified Virus Vectors and Methods of Making and Using the Same

Номер: US20120009268A1

The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. In particular embodiments, the modification comprises a substitution of one or more amino acids at amino acid positions 585 to 590 (inclusive) of the native AAV2 capsid protein sequence or the corresponding positions of other AAV capsid proteins. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo.

Подробнее
12-01-2012 дата публикации

Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell

Номер: US20120010124A9
Принадлежит: Diatos SA

The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions, methods of use and methods for producing such conjugates are also disclosed.

Подробнее
12-01-2012 дата публикации

Self-assembling peptides for regeneration and repair of neural tissue

Номер: US20120010140A1
Принадлежит: Massachusetts Institute of Technology

The present invention provides methods and compositions for enhancing regeneration and/or repair of neural tissue. One method include providing a nanoscale structured material at the site of injury, wherein the nanoscale structured material provides an environment that is permissive for regeneration of neural tissue and allows axon growth from a location on one side of a site of injury or barrier to a location on the other side of the site of injury or barrier. A second method includes introducing a composition comprising self-assembling peptides into the subject at the site of injury, wherein the peptides are amphiphilic peptides that comprise substantially equal proportions of hydrophobic and hydrophilic amino acids and are complementary and structurally compatible. A variety of compositions comprising a nanoscale structured material or precursor thereof, and an additional substance such as a regeneration promoting factor, are also provided. In certain embodiments of the invention the nanoscale structured material or precursor thereof comprises self-assembling peptides. The invention further provides compositions and methods for repair of an intervertebral disc, including nucleus pulpusos repair.

Подробнее
12-01-2012 дата публикации

Methods of treating neurodegenerative disorders and diseases

Номер: US20120010196A1
Автор: Quingyu QIN, Xiaoning Bl
Принадлежит: WESTERN UNIVERSITY OF HEALTH SCIENCES

This invention is directed to a novel method of treating neurodegenerative disorders and diseases. Another, related aspect of this invention is directed to a screening method of identifying compounds that can be used to treat neurodegenerative disorders and diseases. The foregoing aspects of the invention particularly relate to neurodegenerative disorders and diseases have degeneration of neuronal axons as part of their pathologies. The method of treatment involves administering a pharmaceutical formulation that comprises a compound or mixture of compounds that inhibits one or more intracellular signaling mechanism that regulate axon degeneration or growth cone collapse. The screening method aspect of the invention identifies test compounds that can be used for the treatment or prevention of neurodegenerative disorders based on the test compound's ability to inhibit axon degeneration or growth cone collapse.

Подробнее
12-01-2012 дата публикации

5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof

Номер: US20120010239A1
Автор: Ulf Tomas Fristedt
Принадлежит: Teva Pharmaceutical Industries LTD

The subject invention provides 5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, its salts and uses.

Подробнее
12-01-2012 дата публикации

Acetylene derivatives having mglur 5 antagonistic activity

Номер: US20120010263A1
Принадлежит: Individual

The invention provides compounds of formula I wherein n, A, R, R′, R″, R O , X and Y are as defined in the description, and their preparation. The compounds of formula I are useful as pharmaceuticals.

Подробнее
12-01-2012 дата публикации

Modulation of anxiety through blockade of anandamide hydrolysis

Номер: US20120010283A1

Fatty acid amide hydrolase inhibitors of the Formula: are provided wherein X is NH, CH 2 , O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or unsubstituted aryl; substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or unsubstituted phenyl; substituted or unsubstituted terphenylyl; substituted or unsubstituted cycloalkyl, heteroaryl, or alkyl; and R 1 and R 2 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted phenyl, substituted or unsubstituted biphenylyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; with the proviso that if Z is O, one of R 1 and R 2 is absent, and that if Z is N, optionally R 1 and R 2 may optionally be taken together to form a substituted or unsubstituted N-heterocycle or substituted or unsubstituted heteroaryl with the N atom to which they are each attached. Pharmaceutical compositions comprising the compounds of Formula I and methods of using them to inhibit FAAH and/or treat appetite disorders, glaucoma, pain, insomnia, and neurological and psychological disorders including anxiety disorders, epilepsy, and depression are provided.

Подробнее
19-01-2012 дата публикации

Methods and compositions for cns delivery of heparan n-sulfatase

Номер: US20120014936A1
Принадлежит: Shire Human Genetics Therapies Inc

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A.

Подробнее
19-01-2012 дата публикации

Il-1beta binding antibodies and fragments thereof

Номер: US20120014967A1
Принадлежит: Xoma Technology Ltd USA

An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency.

Подробнее
19-01-2012 дата публикации

Compositions with reduced dimer formation

Номер: US20120014978A1
Принадлежит: Circassia Ltd

The present invention relates to the use of a non-reducing carbohydrate or carbohydrate derivative and at least one agent which inhibits dimer formation in a freeze-dried composition comprising at least one peptide that contains a free cysteine residue, to provide a freeze-dried composition with improved long-term storage stability.

Подробнее
19-01-2012 дата публикации

Dna vaccine for alzheimer's disease

Номер: US20120014987A1
Автор: Yoh Matsumoto

The present invention aims to provide a DNA vaccine for Alzheimer's disease. The present invention provides a recombinant vector which comprises DNA encoding amyloid β and DNA encoding a Th2 cytokine, as well as a DNA vaccine for Alzheimer's disease which comprises this vector.

Подробнее
19-01-2012 дата публикации

PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS

Номер: US20120014989A1
Принадлежит: Incyte Corp

The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.

Подробнее
19-01-2012 дата публикации

Modified release formulations containing drug-ion exchange resin complexes

Номер: US20120015030A1
Автор: Ketan Mehta, Yu-Hsing Tu
Принадлежит: Tris Pharma Inc

A solid dose composition containing a mixture of a cured, modified release-barrier coated methylphenidate-ion exchange resin complex-matrix and an uncoated methylphenidate-ion exchange resin complex is described. The barrier coated methylphenidate-ion exchange resin complex-matrix comprises methylphenidate complexed with a pharmaceutically acceptable ion-exchange resin to form the complex which is admixed with a polymer to form a methylphenidate-ion exchange resin complex-matrix, which is subsequently coated with a modified release coating. The modified coating contains polyvinyl acetate polymer and a plasticizer and is cured.

Подробнее
19-01-2012 дата публикации

Enterically coated cysteamine, cystamine and derivatives thereof

Номер: US20120015038A1
Принадлежит: UNIVERSITY OF CALIFORNIA

The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

Подробнее
19-01-2012 дата публикации

Complement receptor 2 targeted complement modulators

Номер: US20120015871A1

Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

Подробнее
19-01-2012 дата публикации

Kallikrein-inhibitor therapies

Номер: US20120015881A1
Принадлежит: Dyax Corp

Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.

Подробнее
19-01-2012 дата публикации

Novel compounds as cannabinoid receptor ligands

Номер: US20120015929A1
Принадлежит: ABBOTT LABORATORIES

Disclosed herein are compounds of formula (I) wherein R 1 , R 2 , R 3 , R 25a , R 26a , X, and n are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions are also described.

Подробнее
19-01-2012 дата публикации

Sulfone Compounds Which Modulate The CB2 Receptor

Номер: US20120015988A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Подробнее
19-01-2012 дата публикации

Growth factor htter36

Номер: US20120016107A1
Принадлежит: Human Genome Sciences Inc

The present invention discloses Growth Factor HTTER36 (GDF3) polypeptides and polynucleotides encoding such polypeptides. Also provided are antibodies that bind HTTER36, including chimeric, humanized, and single chain antibodies.

Подробнее
19-01-2012 дата публикации

Enzymes and methods for producing omega-3 fatty acids

Номер: US20120016144A1
Принадлежит: Individual

The present invention relates generally to the field of recombinant fatty acid synthesis, particularly in transgenic plants. The application describes genes involved in fatty acid synthesis and provides methods and vectors for the manipulation of fatty acid composition of plant oils. In particular, the invention provides constructs for achieving the integration of multiple heterologous genes involved in fatty acid synthesis into the plant genome, such that the resulting plants produce altered levels of polyunsaturated fatty acids. Also described are methods for enhancing the expression of fatty acid biosynthesis enzymes by co-expressing a silencing suppressor within the plant storage organ.

Подробнее
26-01-2012 дата публикации

Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System

Номер: US20120020915A1

Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.

Подробнее
26-01-2012 дата публикации

Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects

Номер: US20120020951A1
Принадлежит: Individual

Provided herein are methods for ameliorating an adverse effect of systemic administration of a PEG hyaluronan degrading enzyme to a subject. The methods involve systemically administering a PEGylated hyaluronan degrading enzyme, particularly a PEGylated hyaluronidase, such as any of the animal or bacterial hyaluronidases, to the subject and administering an amount of a corticosteroid sufficient to ameliorate the adverse effect. Also provided are method of treating a hyaluronan-associated disease or condition for single-agent therapy or combination therapy.

Подробнее
26-01-2012 дата публикации

Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof

Номер: US20120021002A1
Принадлежит: New York University NYU

The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed.

Подробнее
26-01-2012 дата публикации

Garcinia Mangostana L. and Iridoid Based Formulations

Номер: US20120021079A1
Принадлежит: Individual

Embodiments of the invention relate to fortified food and dietary supplement products, which may be administered to produce desirable physiological improvement. In particular, embodiments of the invention relate to the administration of products enhanced with Garcinia mangostana L. and iridoids.

Подробнее
26-01-2012 дата публикации

Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle

Номер: US20120022001A1
Автор: David F. Driscoll
Принадлежит: STABLE SOLUTIONS LLC

A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously.

Подробнее
26-01-2012 дата публикации

Triazole derivatives for treatment of alzheimer's disease

Номер: US20120022044A1
Принадлежит: Individual

According to the invention there is provided a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof; wherein the variables are as defined herein. The compounds selectively attenuate the production of Aβ42 and hence are useful in treatment of Alzheimer's disease and related conditions.

Подробнее
26-01-2012 дата публикации

Process for the purification of eslicarbazepine acetate

Номер: US20120022047A1
Принадлежит: Glenmark Generics LTD

The present invention relates to the purification and particle size of eslicarbazepine acetate. The present invention also relates to the physical characteristics of solid state eslicarbazepine acetate, and pharmaceutical compositions containing the same.

Подробнее
26-01-2012 дата публикации

Histamine h3 inverse agonists and antagonists and methods of use thereof

Номер: US20120022050A1
Принадлежит: SUNOVION PHARMACEUTICALS INC

Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

Подробнее
26-01-2012 дата публикации

Derivatives of n-(arylamino)sulfonamides as inhibitors of mek

Номер: US20120022076A1
Принадлежит: Individual

This invention concerns N-(2-arylamino)aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.

Подробнее
26-01-2012 дата публикации

Pyrrolidine triple reuptake inhibitors

Номер: US20120022125A1
Автор: Jianguo Ma, Liming Shao
Принадлежит: SUNOVION PHARMACEUTICALS INC

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Подробнее
26-01-2012 дата публикации

Short Interfering Ribonucleic Acid (siRNA) for Oral Administration

Номер: US20120022139A1
Принадлежит: NOVARTIS AG

Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.

Подробнее
26-01-2012 дата публикации

Methods for making 3-o-protected morphinones and 3-o-protected morphinone dienol carboxylates

Номер: US20120022259A1
Автор: Andreas Stumpf
Принадлежит: Purdue Pharma LP

Disclosed are methods for making aldehydes and ketones comprising allowing the corresponding primary or secondary alcohol to react in the presence of trichoroisocyanuric acid, a compound of formula R 1 SR 2 and a base. In one embodiment, the alcohol is a compound of formula (I): wherein R 3 is a protecting group. Also disclosed are methods for making 3-O-protected morphine dienol carboxylates comprising allowing a compound of formula (I) to oxidize in the presence of a chlorine-containing compound and a compound of formula R 1 SR 2 ; and allowing the product of the oxidation step to react with an acylating agent.

Подробнее
02-02-2012 дата публикации

Transdermal pharmaceutical preparations

Номер: US20120024743A1
Принадлежит: EGIS PHARMACEUTICALS PLC

The present invention relates to semisolid transdermal pharmaceutical preparation having enhanced stability and bioavailability, wherein the particles are coated by a volatile silicon oil component and the thus obtained suspension is dispersed in a gel or cream base.

Подробнее
02-02-2012 дата публикации

Hk1-binding proteins

Номер: US20120027686A1
Принадлежит: Dyax Corp

The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.

Подробнее
02-02-2012 дата публикации

Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis

Номер: US20120027718A1
Принадлежит: Teva Pharmaceutical Industries LTD

The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, rasagiline or the pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject.

Подробнее
02-02-2012 дата публикации

Methods for treating diabetes

Номер: US20120027729A1
Принадлежит: Tulane University

Transplantation of multipotent stromal cells (MSCs) into diabetic mice lowers blood sugar, increases blood insulin levels, increases the number and size of islets, and improves renal pathology. Accordingly, the invention provides methods for treating or preventing diabetes by administering isolated MSCs. The invention also provides methods for treating or preventing complications which arise from diabetes, including diabetic nephropathy, by transplanting isolated MSCs.

Подробнее
02-02-2012 дата публикации

Methods for treating adult respiratory distress syndrome

Номер: US20120027742A1
Принадлежит: Columbia University of New York

We have discovered that the activated phosphorylated form of focal adhesion kinase (hereafter “FAKp”) strengthens the microvascular endothelial cell (EC) junctions that form a barrier in pulmonary endothelia, and the increased barrier helps to prevent acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Thus certain embodiments of the invention are directed to prevention and treatment of ALI and ARDS by administering a therapeutically effective amount of FAKp to subjects at risk of developing or diagnosed as having either ALI or ARDS.

Подробнее
02-02-2012 дата публикации

Antibody gene transfer and recombinant aav therefor

Номер: US20120027798A1
Принадлежит: Nationwide Childrens Hospital Inc

The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified.

Подробнее
02-02-2012 дата публикации

Nicotine immunonanotherapeutics

Номер: US20120027808A1
Автор: Matteo Iannacone

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface having a plurality of nicotine moieties. The invention provides pharmaceutical compositions comprising nanocarriers. The present invention provides methods of designing, manufacturing, and using nanocarriers and pharmaceutical compositions thereof. For example, the present invention describes nanocarriers capable of eliciting an immune response and the production of anti-nicotine antibodies.

Подробнее
02-02-2012 дата публикации

Isolation, Purification, and Structure Elucidation of the Antiproliferative Compound Coibamide A

Номер: US20120028905A1

Novel antiproliferative compounds, compositions comprising the same, and methods of use thereof are disclosed.

Подробнее
02-02-2012 дата публикации

Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications

Номер: US20120028922A1
Автор: Fotini Sampalis
Принадлежит: Individual

A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.

Подробнее
02-02-2012 дата публикации

Pyrazole compounds as crth2 antagonists

Номер: US20120028938A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity, wherein W, L 1 , L 2 , X, L 3 , Y, R 1 and R 2 are as defined in the specification and claims, to their use as medicaments and to pharmaceutical formulations, containing said compounds or containing a combination of said compounds with one or more active substances.

Подробнее
02-02-2012 дата публикации

Bicyclic mglur5 positive allosteric modulators and methods of making and using same

Номер: US20120028955A1

In one aspect, the invention relates to bicyclic mGluR5 positive allosteric modulators, for example 6-(phenylethynyl)-3,4-dihydroisoquinolin-1(2H)-one, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Подробнее
02-02-2012 дата публикации

6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist

Номер: US20120028961A1
Принадлежит: Eli Lilly and Co

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT 2C receptor agonists for the treatment of 5-HT 2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R 6 is —S—R 14 ; and other substituents are as defined in the specification.

Подробнее
02-02-2012 дата публикации

Novel compound having 3-heteroarylpyrimidin-4-(3h)-one structure and pharmaceutical preparation containing same

Номер: US20120028983A1
Принадлежит: Kowa Co Ltd

Disclosed is a compound which has both an angiotensin-II receptor antagonistic activity and a PPARγ activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, renal diseases, arteriosclerosis, inflammatory diseases, type-2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinemia. [In the formula, A represents a 5- to 10-membered heteroaryl group; R 1 and R 2 independently represent a C 1-6 alkyl group; and each of R 3 to R 5 is absent or represents H, a halogen atom, OH, NO 2 , a halo-C 1-6 alkyl group, a (substituted) C 1-6 alkoxy group, a (substituted) C 3-6 cycloalkyloxy group, or a 5- to 10-membered heteroaryl group.]

Подробнее
02-02-2012 дата публикации

Derivatives of aminocyclobutane or aminocyclobutene, their method of preparation and their use as medical products

Номер: US20120029013A1
Принадлежит: Pierre Fabre Medicament SA

The present invention concerns compounds of general formula (1), where in:—-a- is a single or double bond, Ar is an aromatic group, substituted or unsubstituted, R1 and R2 each independently or together are: a hydrogen atom or C 1 -C 6 alkyl group, branched or unbranched, saturated or unsaturated, substituted or unsubstituted; the groups R1 and R2 may also form a heterocycle, R3 and R3′ each independently or together are a hydrogen atom or C 1 -C 6 alkyl group, X is an oxygen atom or a sulphur atom, and the addition salts of the compounds of general formula (1) with pharmaceutically acceptable mineral acids or organic acids.

Подробнее
02-02-2012 дата публикации

Short Interfering Ribonucleic Acid (siRNA) for Oral Administration

Номер: US20120029052A1
Принадлежит: NOVARTIS AG

Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.

Подробнее
02-02-2012 дата публикации

Use of flavones for treating psychiatric disorders with sensorimotor gating deficits

Номер: US20120029066A1

Novel Use of flavones having 2-phenylchromen-4-one skeleton is disclosed herein. The flavones are useful as lead compounds for manufacturing a medicament or a pharmaceutical composition for treating a patient diagnosed with a psychiatric disorder with sensorimotor gating deficits.

Подробнее
02-02-2012 дата публикации

Compositions and methods for treating or preventing radiation injury

Номер: US20120029071A1
Принадлежит: JOHNS HOPKINS UNIVERSITY

The invention provides compositions and methods featuring Nrf2 activators for treating or preventing radiation-associated tissue damage.

Подробнее
02-02-2012 дата публикации

Anti-anxiety composition

Номер: US20120029088A1
Принадлежит: JX Nippon Oil and Energy Corp

This invention provides a highly safe anti-anxiety composition that can be used for treatment or prevention of anxiety disorders. Such anti-anxiety composition comprises, as an active ingredient, a carotenoid.

Подробнее
02-02-2012 дата публикации

Novel Crystalline Form of Atorvastatin Hemi-calcium Salt, Hydrate Thereof, And Method of Producing The Same

Номер: US20120029207A1
Принадлежит: KYONGBO PHARM

The present invention provides a novel crystalline form of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-mthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptanoic acid hemi-calcium salt (atorvastatin hemi-calcium salt) of the following formula 1, which is known to be useful as a drug, a hydrate thereof and a preparation method thereof:

Подробнее
09-02-2012 дата публикации

Treatment of neurotrophic factor mediated disorders

Номер: US20120034193A1
Принадлежит: Phytopharm Ltd

An agent selected from A/B-cis furostane, furostene, spirostane and spirostene steroidal sapogenins and ester, ether, ketone and glycosylated forms thereof is used to induce self-regulated homeostasis of neurotrophic factors (NFs), for example BDNF and/or GDNF, NFs with limited and manageable side effects in a subject, by modulating NFs in a non-toxic manner under homeostatic control. An effective amount of at least one such agent is administered to the subject, particularly in the treatment or prevention of a range of NF-mediated disorders, particularly neurological, psychiatric, inflammatory, allergic, immune and neoplastic disorders, and in the restoration or normalisation of neuronal and other function in or in relation to any damaged or abnormal tissue, including when assisting tissue (for example, skin, bone, eye and muscle) healing and general skin, bone, eye and muscle health.

Подробнее
09-02-2012 дата публикации

Reduced-cholesterol dairy product for use as a medicament

Номер: US20120034308A1
Автор: Daniel Dalemans
Принадлежит: Corman SA

A ruminant reduced-cholesterol dairy product is used as a medicament.

Подробнее
09-02-2012 дата публикации

Compositions and methods for the treatment of immune related diseases

Номер: US20120035073A1
Принадлежит: Individual

The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.

Подробнее
09-02-2012 дата публикации

Irak kinase family as novel target and biomarker for alzheimer

Номер: US20120035076A1

The present invention relates to methods and devices for the diagnosis or drug response prediction of neurological disorders by measuring kinase activity and studying the phosphorylation levels and profiles in samples of said patients. Furthermore the present invention relates to methods of identifying drug compounds relevant to neurological disorders by measuring kinase activity and studying phosphorylation levels. Also, the present invention relates to the use of inhibitors of the IRAK protein kinase family or a pharmaceutical composition thereof in the treatment of neurological disorders such as Alzheimer's disease.

Подробнее
09-02-2012 дата публикации

Neuronal differentiation-inducing peptide and use thereof

Номер: US20120035112A1
Принадлежит: TOAGOSEI CO LTD

A neuronal differentiation inducer provided by the present invention contains an artificially synthesized peptide which includes an amino acid sequence constituting a signal peptide in amyloid precursor protein (APP), or a partial sequence of the amino acid sequence constituting this signal peptide.

Подробнее
09-02-2012 дата публикации

Glycolipids as treatment for disease

Номер: US20120035120A1
Автор: Shawn Defrees
Принадлежит: Seneb Biosciences Inc

This invention provides compounds, compositions, and methods for treating a disorder selected from cancer, hyperinsulinemia, hypoglycemia, hyperinsulinemia with hypoglycemia, atypical Parkinson's disease, Huntington's disease, multiple systems atrophy, GM3 synthase deficiency, GM2 synthase deficiency or tauopathy.

Подробнее
09-02-2012 дата публикации

Substituted dihydropyrazolones and their use

Номер: US20120035151A1
Принадлежит: Bayer Pharma AG

The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing.

Подробнее
09-02-2012 дата публикации

Modulators of Cellular Adhesion

Номер: US20120035154A1
Принадлежит: Sarcode Bioscience Inc

The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R 1 -R 4 , n, p, A, B, D, E, L and AR 1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).

Подробнее
09-02-2012 дата публикации

Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies

Номер: US20120035230A1
Принадлежит: ProteoTech Inc

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Подробнее
09-02-2012 дата публикации

Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging

Номер: US20120035250A1
Принадлежит: Phenomenome Discoveries Inc

Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).

Подробнее
16-02-2012 дата публикации

Methods of treating pain

Номер: US20120039866A1
Автор: Daniela Salvemini
Принадлежит: St Louis University

The invention relates to methods for treating pain disorders including neuropathic and inflammatory pain and to methods to reduce or eliminate nociceptive tolerance induced by opiate analgesic use by administering an agent that suppresses or blocks S1P biological activity.

Подробнее
16-02-2012 дата публикации

Method of treatment of neurodementing diseases using isolated, monoclonal, human, anti-b-amyloid antibody

Номер: US20120039897A1
Принадлежит: Philipps Universitaet Marburg

Isolated, monoclonal, human, anti-β-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an Aβ polypeptide comprising Aβ(21-37) shield Aβ(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formulation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

Подробнее
16-02-2012 дата публикации

Chewing Gum And Particulate Material For Controlled Release Of Active Ingredients

Номер: US20120039981A1
Принадлежит: Fertin Pharma AS

A particulate material for controlled release of active ingredients includes a combination of one or more active ingredients, including nicotine, and an inorganic mineral filler, in which the active ingredient is reversibly absorbed into and/or adsorbed onto the inorganic mineral filler, and the BET specific surface area of the inorganic mineral filler is above 15 m 2 /g, the BET specific surface area measured in accordance with ISO 9277. Further, a chewing gum having the particulate material includes a combination of one or more active ingredients, such as nicotine or a flavoring agent, and an inorganic mineral filler. Finally, the method of producing the chewing gum is provided. The invention is particularly advantageous for controlled release of active ingredients.

Подробнее
16-02-2012 дата публикации

Method of detecting progression of a neurodementing disease

Номер: US20120040382A1
Принадлежит: Philipps Universitaet Marburg

Isolated, monoclonal, human, anti-β-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an Aβ polypeptide comprising Aβ(21-37) shield Aβ(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

Подробнее
16-02-2012 дата публикации

Methods and materials for delivering molecules

Номер: US20120040432A1

This document relates to methods and materials involved in delivering molecules to a mammal. For example, methods and materials for using nanoparticles to increase the half-life and the bioavailability of molecules administered to a mammal are provided.

Подробнее
16-02-2012 дата публикации

Identification of novel antagonist toxins of t-type calcium channel for analgesic purposes

Номер: US20120040909A1

A peptide with the following sequence YCQKFLWTCDSERPCCEGLVCRLWCKIN (SEQ ID NO 1) or a derivative thereof, and nucleic acids coding for the peptide having the sequence (SEQ ID NO 1). Also the use of this peptide as an antagonist and/or reverse agonist of T-type calcium channels. A use of the peptide for preparing a drug, in particular an analgesic one.

Подробнее
16-02-2012 дата публикации

Tetracyclic terpene series compounds, methods for preparing same, uses thereof as medicines and pharmaceutical compounds containing same

Номер: US20120040930A1

The invention concerns a triterpene alkaloid of general formula (I). The invention also concerns a method for making same and use thereof as medicine.

Подробнее
16-02-2012 дата публикации

Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders

Номер: US20120040940A1
Принадлежит: Pharnext SA

The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related peripheral neuropathies. More particularly, the invention relates to combined therapies for treating said disease by affecting simultaneously muscarinic receptor signaling and thyroid hormone pathway in a subject.

Подробнее
16-02-2012 дата публикации

Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof

Номер: US20120040984A1
Принадлежит: SANOFI SA

The invention relates to compounds of the formula (I) either (i) in the state of a base or an acid addition salt, or (ii) in the state of an acid or a base addition salt, as well as to a method for preparing same and to the therapeutic applications thereof.

Подробнее
16-02-2012 дата публикации

Benzimidazoles which have activity at m1 receptor and their uses in medicine

Номер: US20120041027A1
Принадлежит: Glaxo Group Ltd

Compounds of formula (I) and salts and solvates are provided: wherein Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.

Подробнее
16-02-2012 дата публикации

Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists

Номер: US20120041031A1
Принадлежит: Allergan Inc

Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha 2 receptor agonist.

Подробнее
16-02-2012 дата публикации

Hydroxybenzoate salts of metanicotine compounds

Номер: US20120041033A1
Принадлежит: Individual

Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.

Подробнее
16-02-2012 дата публикации

Substituted acylguanidine derivatives (as amended)

Номер: US20120041036A1
Принадлежит: Astellas Pharma Inc

An object of the present invention is to provide an excellent agent for treating or preventing dementia, schizophrenia based on serotonin 5-HT 5A receptor modulating action. It was discovered that acylguanidine derivatives, in which the guanidine is bonded to one ring of a naphthalene via a carbonyl group and a cyclic group is bonded to the other ring thereof, exhibit potent the 5-HT 5A receptor modulating action and excellent pharmacological actions based on the action. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder or attention deficit hyperactivity disorder.

Подробнее
23-02-2012 дата публикации

Methods and uses of hypoxic compartment cells

Номер: US20120045419A1
Принадлежит: UNIVERSITY HEALTH NETWORK

The disclosure relates to methods of maintaining and/or expanding an in vitro population of hypoxia compartment cells comprising culturing said population of cells optionally in an oxygen controlled environment, wherein the population of hypoxia compartment cells is exposed to an oxygen concentration of between about 1.5% and about 10%, preferably between about 2% and about 5%, and uses of cells expanded according to these methods.

Подробнее
23-02-2012 дата публикации

Engineered anti-il-13 antibodies, compositions, methods and uses

Номер: US20120045438A1
Принадлежит: Centocor Ortho Biotech Inc

The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.

Подробнее
23-02-2012 дата публикации

TNF-alpha Antagonists Containing IGFBP5

Номер: US20120046217A1

The present invention relates to: TNF-α antagonists containing IGFBP5 protein, variants thereof, or fragments thereof; and the use of the TNF-α antagonists. More specifically, the present invention relates to: a polynucleotide encoding the protein, variants thereof, or fragments thereof; a vector containing the polynucleotide; a transformant containing the vector; and a method for screening a therapeutic agent for TNF-α overexpression-related diseases by checking whether the mutual reaction thereof is facilitated after treating with candidates to the cell expressing the IGFBP5 protein, variants thereof, or fragments thereof, and the TNER1.

Подробнее
23-02-2012 дата публикации

Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases

Номер: US20120046270A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention encompasses compounds of general formula (1), wherein the groups R 1 to R 4 , X 1 , X 2 , X 3 , X 4 , X 5 , Q, L 1 and L 2 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, as well as pharmaceutical preparations and formulations of these compounds.

Подробнее
23-02-2012 дата публикации

Compounds and compositions for cognition-enhancement, methods of making, and methods of treating

Номер: US20120046273A1
Принадлежит: Mithridion Inc

Muscarinic agonists, which are useful for stimulating muscarinic receptors and treating cognitive disorders, are provided. Methods of synthesizing such agonists also are provided. Also provided are compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. Also provided are methods of treating animals such as humans by administering such compositions.

Подробнее
23-02-2012 дата публикации

Compounds for treating neuropsychiatric conditions

Номер: US20120046283A1
Принадлежит: Afraxis Inc

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of neuropsychiatric conditions.

Подробнее
23-02-2012 дата публикации

3-substituted propanamine compounds

Номер: US20120046312A1
Принадлежит: SK Biopharmaceuticals Co Ltd

Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containing the subject compounds are also disclosed. The subject compounds are useful for the treatment of diseases of the central nervous system, such as depression, anxiety and pain disorders.

Подробнее